Bcl-2 and Bcl-xL Suppress Glucose Signaling in Pancreatic β-Cells
B-cell lymphoma 2 (Bcl-2) family proteins are established regulators of cell survival, but their involvement in the normal function of primary cells has only recently begun to receive attention. In this study, we demonstrate that chemical and genetic loss-of-function of antiapoptotic Bcl-2 and Bcl-xL significantly augments glucose-dependent metabolic and Ca2+ signals in primary pancreatic β-cells. Antagonism of Bcl-2/Bcl-xL by two distinct small-molecule compounds rapidly hyperpolarized β-cell mitochondria, increased cytosolic Ca2+, and stimulated insulin release via the ATP-dependent pathway in β-cell under substimulatory glucose conditions. Experiments with single and double Bax–Bak knockout β-cells established that this occurred independently of these proapoptotic binding partners. Pancreatic β-cells from Bcl-2−/− mice responded to glucose with significantly increased NAD(P)H levels and cytosolic Ca2+ signals, as well as significantly augmented insulin secretion. Inducible deletion of Bcl-xL in adult mouse β-cells also increased glucose-stimulated NAD(P)H and Ca2+ responses and resulted in an improvement of in vivo glucose tolerance in the conditional Bcl-xL knockout animals. Our work suggests that prosurvival Bcl proteins normally dampen the β-cell response to glucose and thus reveals these core apoptosis proteins as integrators of cell death and physiology in pancreatic β-cells.
Type 2 diabetes involves combined defects in β-cell function and mass. Therapeutic efforts to combat diabetes could benefit from a better understanding of proteins that control both β-cell physiology and apoptosis. Cell survival is tightly regulated by signaling pathways that converge on pro- and antiapoptotic proteins from the B-cell lymphoma 2 (Bcl-2) family. Prominent antiapoptotic members include Bcl-2, Bcl-xL, and Mcl-1, whereas key apoptosis-inducing members include Bax, Bak, and the structurally distinct members Bad, Bid, and Bim (1,2). Elegant work from Danial et al. (3) demonstrated that Bad has a physiological role in β-cells, aside from its role in β-cell apoptosis. Specifically, Bad phosphorylated at serine 155 promotes glucose-stimulated insulin secretion via interactions with glucokinase (3). It is not known whether any other Bcl family members play roles in β-cell physiology. The best understood of the prosurvival proteins, Bcl-2 and Bcl-xL, have been implicated in the control of β-cell survival under stress (4,5), but little is known about the roles of these proteins in healthy β-cells. Studies in other cell types have suggested that Bcl-2 and Bcl-xL regulate Ca2+ homeostasis (6) and mitochondrial physiology (7,8). Given the unique roles for mitochondria and Ca2+ in β-cell glucose signaling, we hypothesized that prosurvival Bcl proteins may be important in normal β-cell function.
To date, most studies of antiapoptotic Bcl proteins in β-cells have relied on forced overexpression (9–11). In this study, we examined the roles of endogenous prosurvival Bcl proteins in pancreatic β-cells using complementary loss-of-function approaches, small molecule Bcl-2/Bcl-xL antagonists, as well as Bcl-2 and Bcl-xL knockout mice. Our results demonstrate the combined importance of Bcl-2 and Bcl-xL for mitochondrial integrity and β-cell survival and reveal distinct roles for the endogenous proteins in metabolic signaling, Ca2+ homeostasis, and insulin secretion. Our findings place these important members of the core apoptotic machinery at the interface of β-cell survival and physiology.
RESEARCH DESIGN AND METHODS
Compound-6 (also known as Bcl-2 inhibitor) and YC137 (also known as Bcl-2 inhibitor II) from Calbiochem (La Jolla, CA) were prepared in dimethyl sulfoxide. Fura-2/AM, Rhodamine123, and MitoTracker were from Life Technologies/Invitrogen (Burlington, Ontario, Canada). Propidium iodide (PI), nifedipine, diazoxide, sodium azide, and tetramethylrhodamine ethyl ester perchlorate (TMRE) were from Sigma-Aldrich (St. Louis, MO).
Imaging and flow cytometry.
Dispersed islet cells and intact islets were imaged following 24–48 h culture on glass coverslips. Changes in cytosolic Ca2+, mitochondrial membrane potential (ΔΨm), and NAD(P)H autofluorescence were imaged as described (12,13). Mitochondrial Ca2+, endoplasmic reticulum (ER) Ca2+, and the activation of caspase-3 were monitored in single MIN6 cells transfected with fluorescence resonance energy transfer (FRET)-based biosensors. MIN6 cell ΔΨm was estimated using TMRE and flow cytometry (14). Late-stage cell death was imaged using PI (14).
To examine changes in the ATP/ADP ratio, MIN6 cells in 96-well plates were equilibrated for 30 min in Krebs Ringer Buffer (KRB) containing (in mM unless otherwise noted): 119 NaCl, 4.7 KCl, 25 NaHCO3, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 5 mg/mL radioimmunoassay-grade bovine albumin, and 3 mmol/L glucose, followed by treatment for 30 min as indicated. ATP/ADP ratios were measured using the ApoSENSOR kit (BioVision, Mountain View, CA) using a TECAN M1000 luminometer (Tecan Group Ltd.).
Glucose oxidation rates were determined in cultures of dispersed islet cells by quantifying 14CO2 generated from metabolized 14C-labeled glucose as described (15,16). Adherent islet cells in T-25 flasks were preincubated 1 h in 3 mmol/L glucose KRB. This was followed by 1 h incubation with KRB containing 1 μCi/mL [U-14C]glucose and test concentrations of nonlabeled glucose during which 14CO2 was collected in a hyamine trap. Injection of 9 N H2SO4 stopped the reaction and released 14CO2 captured in the media as [14C]bicarbonate. Flasks were gently agitated for 2 h at room temperature before measuring captured radioactivity using a Beckman LS6500 Liquid Scintillation Counter (Beckman Coulter). Glucose oxidation rates were normalized to total protein quantified from identical aliquots of similarly treated cells.
Bax−/− (Jax stock number 002994) and Bak−/− (Jax stock number 004183) mice and age- and background-matched wild-type controls were from The Jackson Laboratory (Bar Harbor, ME). Littermate Bcl-2−/−, Bcl-2+/−, and Bcl-2+/+ mice were obtained by breeding mice heterozygous for the Bcl2tm1Sjk mutation (Jax stock number 002265; The Jackson Laboratory). To generate Bcl-xflox/flox:Pdx1-CreER mice and Bcl-xflox/flox control littermates, we mated Pdx1-CreER mice (17) with Bcl-xflox/flox mice (exons 1 and 2 flanked by Lox P sites) (18). To create mice with double Bax and Bak deletion in their β-cells, we bred Pdx1-CreER animals with Bak−/−:Baxflox/flox mice (Baxtm2SjkBak1tm1Thsn/J; Jax stock number 006329; The Jackson Laboratory) and obtained Bak−/−:Baxflox/flox:Pdx1-CreER and Bak−/−:Baxflox/flox littermates. Ablation of Bcl-x and Bax was achieved by injecting Pdx1-CreER–positive animals and littermate controls with 3 mg/40 g of tamoxifen (Sigma-Aldrich) on 5 consecutive days. Glucose tolerance and in vivo insulin secretion were assessed following intraperitoneal injection with glucose as indicated. Insulin tolerance was assessed after intraperitoneal injection of 0.75 units/kg insulin. Animals were fasted for 6 h prior to study. Studies were approved by the University of British Columbia Animal Care Committee.
Islet isolation, cell culture, and insulin secretion.
Mouse islet isolation by collagenase digestion/filtration and culture have been described (19). Human islets were obtained from Dr. Garth Warnock (Vancouver General Hospital) after consent and cultured as described (12). MIN6 cells were cultured in Dulbecco’s modified Eagle’s medium (25 mmol/L glucose). Insulin release was measured from dispersed mouse islet cells in 48-well plates (20). Cells were equilibrated for 60 min in 3 mmol/L glucose KRB and then stimulated for 45 min with treatments as indicated (20). Insulin secretion from batches of size-matched islets was examined by perifusion and radioimmunoassay as previously described (12).
Immunoblotting and coimmunoprecipitation.
For immunoprecipitation, 500 µg of total protein was incubated overnight (4°C) with anti-Bad (catalog number 9292; Cell Signaling Technology; 1:200), followed by 3-h incubation (4°C) with protein A-agarose (Santa Cruz Biotechnology). Complexes were washed with PBS and protease inhibitors in Ultrafree-MC Filters (Millipore) and eluted using 4% SDS in PBS with protease inhibitors. In some studies, nuclear (PARIS; Ambion Inc.) and mitochondrial fractions (Mitochondrial/Cytosol Kit; BioVision, Inc.) were obtained. Proteins were resolved by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and probed overnight (4°C) for Bcl-xL, Bcl-2, Bax, cytochrome c (catalog numbers 2762, 2870, 2772, and 4272; Cell Signaling Technology); phospho-Bad Ser112, Ser136, and Ser155 (catalog numbers 9291, 4366, and 9297; Cell Signaling Technology), Bad, Bak (#06–536; Millipore), and Cre recombinase (Novagen).
Data are shown as mean ± SEM. Differences between two groups were compared by unpaired Student t test and multiple groups by one-way ANOVA followed by Bonferroni multiple comparison test. Differences were considered significant if P < 0.05.
Kinetic characterization of apoptotic events during prolonged Bcl-2/Bcl-xL antagonism.
We used small-molecule antagonists to probe moment-to-moment functions of Bcl-2 and Bcl-xL in pancreatic β-cells. The structurally distinct inhibitors, compound 6 (C6) and YC137, were originally identified by their ability to bind both Bcl-2 and Bcl-xL and displace proapoptotic members such as Bak and Bid (21,22). We first established that BH3-displacement could also be observed in intact β-cells. Indeed, C6 caused a rapid reduction in the amount of Bcl-xL that was bound to the BH3-only protein Bad without affecting the total levels of Bad or Bcl-xL protein within 1 h (Fig. 1A and B). This confirmed the expected mechanism of this antagonist on endogenous Bcl proteins in intact β-cells.
Displacement of BH3 domain proteins from Bcl-2 and Bcl-xL by YC137 or C6 sensitizes tumor cells to apoptosis, an effect that is more potent with increasing Bcl-2 expression (21,22). Unlike many tumor cells, primary β-cells do not hyperexpress Bcl-2 or Bcl-xL. We therefore tested if these inhibitors affect β-cell survival. Prolonged Bcl antagonism induced dose- and time-dependent cell death in human and mouse islet cells, as well as MIN6 β-cells (Fig. 1C–E). This involved mitochondrial apoptosis, as evidenced by redistribution of Bax from cytosol to mitochondria and release of mitochondrial cytochrome c (Fig. 1F). PI incorporation was preceded by the activation of caspase-3, imaged in real time (Fig. 1G). Of note, the ΔΨm of β-cells treated with C6 or YC137 underwent an initial hyperpolarization that suggested mitochondrial activation within the first half hour, well prior to any evidence of apoptosis. This was followed hours later by collapse of ΔΨm, demonstrating a late-stage loss of mitochondrial integrity (Fig. 1H). These results demonstrate that even in the absence of other stresses, combined and sustained antagonism of Bcl-2 and Bcl-xL initiates mitochondrial apoptosis in β-cells. Importantly, apoptosis was not detected earlier than 2 h, indicating that cellular responses occurring less than an hour after Bcl-2/Bcl-xL antagonism are separate from the central apoptotic events.
Antagonizing Bcl-2/Bcl-xL initiates KATP channel- and depolarization-dependent Ca2+ entry and insulin secretion.
Remarkably, Bcl-2/Bcl-xL antagonists rapidly triggered marked Ca2+ fluctuations in mouse and human islet cells that resembled Ca2+ responses to glucose (Fig. 2A–C). Similar effects were observed in MIN6 β-cells (Fig. 2D). The percentage of cells activated within 30 min of Bcl inhibition was concentration-dependent (Fig. 2E). The Ca2+ signals ceased upon washout of the inhibitor, strongly suggesting a physiological basis rather than cell damage. C6 also increased average cytosolic Ca2+ in intact islets, although the rapid fluctuations were dampened (Fig. 2F). Together, these findings provide the first direct evidence that prosurvival Bcl proteins regulate moment-to-moment calcium homeostasis in β-cells.
Next, we sought to determine the cellular site where Bcl-2 and/or Bcl-xL control Ca2+ homeostasis. In other cell types, Bcl-2 and Bcl-xL reside on the membranes of Ca2+ handling organelles, including the mitochondria, ER, and the nuclear envelope (23,24). The subcellular location of Bcl-2 and Bcl-xL in β-cells has not been reported. We found that Bcl-2:GFP displayed some colocalization with mitochondria, but also had a clear nonmitochondrial distribution, likely reflecting ER (Fig. 3A and D). In contrast, Bcl-xL:yellow fluorescent protein (YFP) showed near-exclusive colocalization with mitochondria, which at high magnification could often be seen in an apparent association with the mitochondrial membrane (Fig. 3B and D) and minimal association with ER (Fig. 3C and D). A differential distribution of endogenous Bcl-2 and Bcl-xL between mitochondrial and nonmitochondrial compartments was also found by subcellular fractionation (Fig. 3E). These findings suggest that β-cell Bcl-2 and Bcl-xL may have overlapping, but distinct, roles.
Bcl-2 and Bcl-xL influence ER Ca2+ release in other cell types (6,25,26). Imaging ER luminal Ca2+ directly (14,27), we found that ER Ca2+ levels were not affected by C6 treatment for up to 50 min (Fig. 4A; similar results seen with 20–80 μmol/L C6). As a positive control, inositol triphosphate generation with carbachol consistently mobilized ER Ca2+ (Fig. 4A). Although these results suggest that acutely antagonizing Bcl-2 and Bcl-xL does not alter β-cell ER Ca2+, it remains possible that Bcl-2 or Bcl-xL regulate β-cell ER Ca2+ homeostasis by mechanisms that are unaffected by these small-molecule antagonists.
Next, we sought to further elucidate the mechanism by which Bcl inhibitors increase cytosolic Ca2+. Similar to stimulatory glucose, Bcl inhibitors had no effect on cytosolic Ca2+ in the absence of extracellular Ca2+ (Fig. 4B). Moreover, the L-type Ca2+ channel antagonist nifedipine reversibly lowered cytosolic Ca2+ during Bcl inhibition (Fig. 4C). Pretreatment of islet cells with nifedipine, the KATP channel agonist diazoxide, or a low dose of the mitochondrial uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP) prevented Ca2+ entry (Fig. 4D). Incubating islet cells with Bcl antagonist in the presence of substimulatory glucose (3 mmol/L) induced a modest, but significant, elevation in insulin release similar in magnitude to that triggered by 100 μmol/L of the KATP channel blocker tolbutamide (Fig. 4E). These insulin-secretion responses were attenuated by diazoxide and were not additive with the response to tolbutamide (Fig. 4E), or with a maximally stimulatory concentration of glucose (fold increase: 3.99 ± 1.12 in 20 mmol/L glucose vs. 3.44 ± 1.06 in 20 mmol/L glucose plus 40 μmol/L C6; n = 7; P = 0.73). Despite their ability to block the acute Ca2+ signals, nifedipine and diazoxide did not alter the degree or the kinetics of islet cell death induced by C6 (Fig. 4F). Together, these data demonstrate that antagonizing Bcl-2/Bcl-xL acutely induces Ca2+ entry and insulin secretion from β-cells by mechanisms similar to those involved in glucose signaling (28) and that these physiological Ca2+ signals are not mechanistically related to the late-stage apoptotic effects of sustained Bcl-2/Bcl-xL coinhibition.
Bcl-2/Bcl-xL inhibition increases mitochondrial activity.
Our results to this point indicated that the events induced by Bcl protein inhibition are similar to those that underlie β-cell glucose signaling. Indeed, sodium azide blocked C6-stimulated Ca2+ signals, establishing a requirement for mitochondrial respiratory flux (Fig. 4G). Importantly, Ca2+ signaling upon Bcl antagonism was suppressed in the absence of glucose (Fig. 2E), suggesting that a minimum of metabolic substrate is required to support the Ca2+ responses. These findings indicate that blocking Bcl-2/Bcl-xL increases basal mitochondrial glucose metabolism rather than acting independently of the sugar.
To further establish if Bcl antagonists promote mitochondrial activity, we directly imaged ΔΨm and mitochondrial Ca2+ (12,14,29). In agreement with our flow cytometry results, Bcl antagonism hyperpolarized the mitochondria of single primary mouse β-cells within minutes in a concentration-dependent manner (Fig. 4H). The ΔΨm changes were comparable to the β-cell response to glucose, and the presence of Bcl-2/Bcl-xL antagonist did not prevent additional glucose-induced hyperpolarization (Fig. 4I). Bcl-2/Bcl-xL inhibition also evoked reversible mitochondrial Ca2+ signals that resembled glucose stimulation (Fig. 4J), providing further evidence for mitochondrial activation. Of note, Bcl antagonism caused an increase in the cellular ratio of ATP to ADP similar to that evoked by 20 mmol/L glucose (Fig. 4K). Our results demonstrate that acute inhibition of Bcl-2/Bcl-xL promotes mitochondrial activity in β-cells, resulting in the same events activated by stimulatory glucose. These findings implicate Bcl-2 and/or Bcl-xL in the regulation of β-cell mitochondrial physiology and suggest that one of their day-to-day roles is to suppress basal glucose metabolism.
Genetic ablation of Bcl-2 enhances β-cell glucose responses.
To validate our experiments with small molecule inhibitors, we examined the importance of Bcl-2 and Bcl-xL in β-cell function in vitro using a genetic loss-of-function approach. First, we used islets from Bcl-2−/− mice. These global knockout mice are approximately half the size of their wild-type or heterozygous littermates, insulin-hypersensitive, develop polycystic kidney disease, and die at various ages between 2 and 19 weeks (30) (D.S.L. and J.D.J., unpublished observations), precluding interpretable in vivo analysis of β-cell function. Nevertheless, we were able to isolate islets for in vitro analysis from a limited number of Bcl-2−/− mice prior to any signs of illness and compare them to islets from phenotypically normal heterozygous and wild-type littermates (31). Real-time PCR confirmed the loss of Bcl-2 expression in Bcl-2−/− and Bcl-2+/− islets relative to Bcl-2+/+ controls, with no compensatory increase in Bcl-xL (Fig. 5A). Bcl-2−/− and Bcl-2+/− β-cells showed enhanced sensitivity to a stepwise glucose ramp stimulus relative to cells from wild-type littermates (Fig. 5B and C). Intact islets from Bcl-2−/− mice also showed increased Ca2+ and metabolic NAD(P)H responses to 6 mmol/L glucose (Fig. 5E and F). In perifusion experiments, we observed significantly increased insulin secretion from Bcl-2−/− islets in response to 10 and 15 mmol/L glucose, compared with Bcl-2+/+ islets (Fig. 5G). Loss of Bcl-2 had no effect on the responses to depolarization with KCl, further indicating a change at the level of β-cell metabolism (Fig. 5D and H). Generally, the effects on intact islets were less pronounced than those in dispersed cells, suggesting that cell–cell coupling may dampen the amplified responses of individual Bcl-2−/− β-cells. The intermediate augmentation of glucose-induced Ca2+ responses in Bcl-2 heterozygous β-cells (Fig. 5B and C) indicates that the effects were dependent on gene dosage and independent of pathological conditions that limit the number of healthy Bcl-2−/− mice available for study. Throughout our studies, we did not notice any obvious differences in the viability of Bcl-2−/− islets or β-cells in culture.
Genetic ablation of Bcl-xL enhances β-cell glucose responses.
Global deletion of Bcl-xL is embryonically lethal (32), so to assess the specific role of Bcl-xL, we generated tissue-specific, tamoxifen-inducible Bcl-xL knockout (BclxβKO) mice. Bcl-xL was knocked out in β-cells of adult animals as early as 2 to 3 days after tamoxifen administration with no compensatory change in Bcl-2 expression (Fig. 6A). Bcl-xL deletion was not observed in hypothalamus (Fig. 6B). Using BclxβKO islet cells, we confirmed a significant molecular contribution of Bcl-xL to C6-induced Ca2+ signals (Fig. 6C). Like Bcl-2−/− β-cells, BclxβKO β-cells showed significantly larger glucose-induced Ca2+ and NAD(P)H responses (Fig. 6D, E, and G), whereas Ca2+ responses to KCl were normal (Fig. 6F). These findings support a metabolic basis for the amplified Ca2+ responses, although we did not detect changes at the level of glucose oxidation in bulk cultures of dispersed BclxβKO islet cells (Fig. 6H). A modest tendency toward increases in insulin secretion was seen in BclxβKO islets perifused with 3, 6, and 10 mmol/L glucose and in mice injected with glucose in vivo, but these did not achieve statistical significance (Figs. 6I and 7A). Interestingly, glucose tolerance was nonetheless moderately improved in BclxβKO mice administered 2 g/kg glucose relative to littermate controls (Fig. 7B). The potentiation of β-cell Ca2+ signals at submaximal glucose prompted us to examine the in vivo response to a more moderate glucose challenge (0.5 g/kg), and indeed glucose tolerance was also improved under these conditions (Fig. 7C and D). This was not associated with improved insulin sensitivity (Fig. 7E). Together, our combined findings using chemical inhibitors and islets from knockout mice point to novel roles for both Bcl-2 and Bcl-xL in the fine-tuning of glucose signaling in pancreatic β-cells.
Bcl-2 and Bcl-xL affect β-cell function independently of Bax and Bak.
Proapoptotic Bax and Bak have been reported to interact with two regulators of mitochondrial physiology: the voltage-dependent anion channel (VDAC) and the adenine nucleotide translocase (ANT) (33–35), but it is not clear if this occurs outside of apoptosis. Given the established roles of Bax and Bak downstream of Bcl-2/Bcl-xL, we asked if they participate in Bcl-2/Bcl-xL regulation of metabolism. Bax−/− or Bak−/− β-cells responded to Bcl-2/Bcl-xL inhibition similar to wild-type β-cells (Fig. 8A). To conclusively exclude the involvement of Bax and Bak, we generated mice lacking both genes in their β-cells (Fig. 8B and C). Islet cells from these Bax–Bak β double-knockout (DKO) mice responded to Bcl-2/Bcl-xL antagonism similar to islet cells from control mice (Fig. 8D and E). Together, these data establish that Bax and Bak do not mediate the effects of Bcl-2 or Bcl-xL in β-cell function and further distinguish the physiological effects of Bcl inhibition from Bax/Bak-dependent apoptotic events.
The current study was undertaken to examine the physiological roles of endogenous prosurvival Bcl proteins in pancreatic β-cells. Using small-molecule Bcl-2/Bcl-xL antagonists and islets from KO mice, we provide the first loss-of-function evidence that Bcl-2 and Bcl-xL acutely affect mitochondrial function, Ca2+ homeostasis, and insulin secretion. A previous report described apoptosis sensitivity in mice in which Bcl-xL was deleted in embryonic β-cells, but did not provide information on glucose homeostasis or β-cell physiology (5). The effects of the chemical inhibitors, which target both Bcl-2 and Bcl-xL, were partially distinct and generally more robust than the genetic ablation of either protein individually. It is likely that combined tissue-specific deletion of Bcl-2 and Bcl-x will be required to mimic the effects of the inhibitors on basal β-cell activity and viability. Our work demonstrates new physiological roles for two proteins previously presumed to function mainly in the control of apoptosis.
Sustained cytosolic Ca2+ rises and insulin release following glucose stimulation rely heavily on mitochondrial ATP synthesis, KATP channel-dependent β-cell depolarization, and voltage-gated Ca2+ influx (28). In this study, we report that acute coinhibition of antiapoptotic Bcl-2 and Bcl-xL stimulates an identical cascade of events culminating in insulin secretion. Moreover, genetic deletion of Bcl-2 or Bcl-xL increased the in vitro β-cell responses to glucose and improved in vivo glucose tolerance of the islet-specific Bcl-xL KO mice. Our experiments suggest that this involves amplification of β-cell glucose metabolism and thus that Bcl-2 and Bcl-xL restrict β-cell metabolic activity. Our findings conceptually agree with a previous study in which mice overexpressing Bcl-xL 10-fold under the control of the rat insulin promoter exhibited impaired β-cell oxidative metabolism and glucose intolerance (9). Several groups have overexpressed Bcl-2 in pancreatic islets as part of efforts to block apoptosis, but we are only aware of a few studies that examined the impact on β-cell function, and these reported no impairment of insulin secretion (36,37). This could be interpreted as evidence for a saturation effect whereby excess levels of Bcl-2 protein do not negatively affect the stoichiometry of complexes associated with the metabolic machinery. Alternatively, the lower fraction of mitochondria-localized Bcl-2 relative to Bcl-xL (Fig. 3) might require that correspondingly larger amounts of Bcl-2 are expressed to achieve detectable metabolic suppression.
We considered that antagonizing Bcl-2/Bcl-xL might free Bax and/or Bak to indirectly activate mitochondria, possibly by affecting ANT or VDAC (33–35). We tested and eliminated this possibility using Bax KO, Bak KO, and Bax/Bak DKO islet cells. Work from the Danial group (3,38) is consistent with an alternative indirect model whereby Bcl-2 and/or Bcl-xL might sequester Bad and limit its promotion of glucokinase activity. Bcl-2 and Bcl-xL have not been detected in the Bad/glucokinase complex, but reducing their binding to Bad might release this brake on β-cell metabolism from afar. In preliminary studies in MIN6 cells, Bcl inhibition did not change Bad levels or phosphorylation within 60 min, the timescale corresponding to the acute Ca2+ signals and metabolic effects. Preliminary studies in Bcl-xL KO islets revealed 58% increase in serine 155 phosphorylation, with no significant effects on the phosphorylation of Bad at serine 136 or serine 112. Thus, phosphorylation-dependent functions of Bad do not appear acutely involved in the effects of Bcl antagonism. However, a more chronic contribution from the Bad/glucokinase axis following chronic Bcl protein loss remains a possibility that might promote the amplification of insulin secretion in stimulatory glucose that is not apparent acutely following inhibition with small molecules.
Our data also allow for a model whereby Bcl proteins directly affect mitochondrial proteins in the β-cell, provided such interactions are changed by Bcl antagonists. Studies of the antiapoptotic activities of Bcl-2 and Bcl-xL have reported that they can interact with mitochondrial ANT and VDAC via their BH4 domains (35). We have found that a cell-permeant Bcl-xL BH4 domain peptide triggers cytosolic and mitochondrial Ca2+ fluctuations in β-cells (D.S.L. and J.D.J. unpublished observations). This could result from direct mitochondrial actions of the BH4 domain and/or ER Ca2+ release (39). Of note, it was recently reported that Bcl-xL can lower acetyl-CoA levels independently of Bax and Bak (40). Another study suggested that Bcl-xL suppresses O2 consumption, although promoting ATP synthesis in neurons by interacting with the mitochondrial F1F0 ATPase (8), indicating that Bcl-xL can have opposing metabolic effects in a cell. Conceivably, changes in the relative contributions of these effects may shape the net metabolic impact of Bcl-xL in a given cell type and might complicate the analysis of complex mechanisms such as insulin secretion that involve multiple metabolic pathways.
Our finding that antiapoptotic Bcl-2 family proteins can modulate β-cell function has intriguing implications for our understanding of the pathophysiology of diabetes. The signal transduction machinery of β-cells is optimized for maximal delivery of glycolytic intermediates for oxidative phosphorylation (41). However, β-cells are remarkably sensitive to the deleterious effects of reactive oxygen species (42). Metabolic suppression may provide a means by which Bcl proteins protect pancreatic β-cells against metabolic stress. One might also speculate that the reduction in Bcl-2 and Bcl-xL seen under prodiabetic conditions (4,43–45) can affect β-cell function. In this regard, it is noteworthy that insulin hypersecretion is an early marker of human diabetes (46), and chronic hyperinsulinemia a persistent feature of diabetic animal models, including the Zucker Diabetic Fatty rat (47), which has 70% less Bcl-2 protein (48). In extension of this, our results suggest caution may be prudent in efforts to treat diabetes by augmenting β-cell metabolic flux using agents such as glucokinase activators (49).
In summary, we demonstrate novel roles of endogenous antiapoptotic Bcl proteins in the physiology of pancreatic β-cells. Specifically, our data suggest that endogenous Bcl-2 and Bcl-xL suppress the β-cell response to glucose. Our findings add to emerging evidence that places Bcl family proteins at the intersection of β-cell function and survival. The involvement of apoptosis-regulating proteins in the normal function of primary cells promises to provide fertile grounds for future insights into the pathophysiology of diabetes and other diseases.
This work was supported by operating grants from the Canadian Institutes of Health Research (CIHR) (MOP-86559 to J.D.J. and MOP-119537 to D.S.L.). J.D.J. was supported by salary awards from the CIHR, the Juvenile Diabetes Research Foundation (JDRF), the Canadian Diabetes Association (CDA), and the Michael Smith Foundation for Health Research (MSFHR). D.S.L. received fellowship support from the JDRF, the Carlsberg Foundation, CDA, and the MSFHR.
No potential conflicts of interest relevant to this article were reported.
D.S.L. designed experiments, performed research, and wrote the manuscript. S.A.W., S.B.W., and V.V.S. performed research, contributed to discussion, and reviewed and edited the manuscript. F.T. performed research. X.H. performed research. M.F.A. contributed to discussion and reviewed and edited manuscript. J.D.J. designed research and wrote the manuscript. J.D.J. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
The authors thank Dr. Douglas Melton, Harvard University, for the Pdx1-CreER mice and Dr. You-Wen He, Duke University, for the Bcl-xflox mice. The authors also thank Dr. Atsushi Miyawaki, RIKEN Japan, for the MiCy-DEVD-mKO probe; Dr. Roger Tsien, University of California San Diego, and Dr. Amy Palmer, University of Colorado, for the mt4D3cpv and D1ER Ca2+ sensors; and Karen Groden, Suzen Lines, and the University of British Columbia rederivation facility for help with husbandry of the Bcl-2 mice.
See accompanying commentary, p. 18.
- Received October 16, 2011.
- Accepted June 16, 2012.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.